Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience

Journal of Viral Hepatitis

Volumn 24, Issue 11, 2017, Pages 927-935

  Hlaing, N K T ^a   Mitrani, R A ^b   Aung, S T ^c   Phyo, W W ^c   Serper, M ^b   Kyaw, A M M ^a   Bwa, A H ^c   Win, K M ^c   Reddy, K R ^b  

^a Mandalay General Hospital   (Myanmar)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Yangon GI and Liver Centre   (Myanmar)

Author keywords

hepatitis C Virus; ledipasvir; peg interferon; ribavirin; sofosbuvir; sustained virologic response

Indexed keywords

DACLATASVIR; LEDIPASVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ADULT; AGED; ANTIVIRAL ACTIVITY; APPETITE DISORDER; ARTHRALGIA; ARTICLE; COHORT ANALYSIS; DENTAL HEALTH; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FIBROSIS; HAIR LOSS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MOUTH HYGIENE; MYALGIA; MYANMAR; NAUSEA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; THYROID DISEASE; TREATMENT DURATION; ADOLESCENT; COMBINATION DRUG THERAPY; FOLLOW UP; GENETICS; GENOTYPE; HEPACIVIRUS; LIVER FUNCTION TEST; MIDDLE AGED; ODDS RATIO; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOMARKERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MYANMAR; ODDS RATIO; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 85020427433     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12721     Document Type: Article

References (35)

1. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24:336-345.
2. Yu M-L, Chuang W-L. New treatments for HCV: perspective from Asia. Clin Liv Dis. 2015;5:17-21.
3. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther. 2012;36:91-103.
4. Sulkowski MS, Cooper C, Hunyady B, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212-223.
5. Ahmed F, Mehdi K. Barriers to directly acting antiviral agent use for chronic hepatitis C in South and South East Asia. SM J Hepat Res Treat. 2015;1:1003.
6. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013;37:921-936.
7. Win NN, Kanda T, Nakamoto S, Yokosuka O, Shirasawa H. Hepatitis C virus genotypes in Myanmar. World J Gastroenterol. 2016;22:6095-6099.
8. Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013;20:669-677.
9. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepatitis. 2011;18:e516-e522.
10. Ampuero J, Romero-Gomez M, Reddy KR. Review article: HCV genotype 3—the new treatment challenge. Aliment Pharmacol Ther. 2014;39:686-698.
11. Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014;39:478-487.
12. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127-1135.
13. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149:1454.e1-1461.e1.
14. Lai CL, Wong VWS, Yuen MF, et al. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Aliment Pharmacol Ther. 2016;43:96-101.
15. Hlaing NK, Banerjee D, Mitrani R, et al. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: a resource-constrained country. World J Gastroenterol. 2016;22:9613-9622.
16. Naing C, Sitt T, Aung AT, Aung K. Sustained virologic response to a dual peginterferon alfa-2a and ribavirin in treating chronic hepatitis C infection: a retrospective cohort study. Medicine (Baltimore). 2015;94:e1234.
17. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-1887.
18. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61:769-775.
19. AASLD-IDSA. Not recommended regimens in HCV treatment. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report/not-recommended-regimens-hcv-treatment. Accessed December 19, 2016.
20. Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702-726.
21. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993-2001.
22. Reddy KR, Lim JK, Kuo A, et al. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther. 2017;45:115-126.
23. AASLD-IDSA. Initial treatment of HCV infection. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection. Accessed December 19, 2016.
24. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-1898.
25. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15:645-653.
26. Cheng G, Tian Y, Doehle B, et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother. 2016;60:1847-1853.
27. Yang R, Cong X, Du S, Fei R, Rao H, Wei L. Performance comparison of the versant HCV genotype 2.0 ASSAY (LiPA) and the Abbott Realtime HCV Genotype II assay for detecting hepatitis C virus genotype 6. J Clin Microbiol. 2014;52:3685-3692.
28. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A. 2001;98:6895-6900.
29. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432:922-924.
30. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599-2607.
31. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol. 2015;7:1617-1631.
32. Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes. 2014;5:52-58.
33. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput J. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25:108-111.
34. Brandman D, Bacchetti P, Ayala CE, Maher JJ, Khalili M. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care. 2012;35:1090-1094.
35. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010;51:307-328.